Quantum Genomics Ownership
| ALQGC Stock | EUR 0.07 0 1.77% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Quantum |
Quantum Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. Quantum Genomics recorded a loss per share of 0.73. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 13th of December 2013. Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people. For more info on Quantum Genomics SA please contact the company at 33 1 85 34 77 70 or go to https://www.quantum-genomics.com.Quantum Genomics Outstanding Bonds
Quantum Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Quantum Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Quantum bonds can be classified according to their maturity, which is the date when Quantum Genomics SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.